The use of surrogate endpoints in trials including biliary tract cancers (BTC) is growing.
While this may expedite drug approval and decrease costs, it may not always correlate with an overall survival (OS) advantage.
We aimed to explore the association of progression-free survival (PFS), objective response rate (ORR) and disease-control rate (DCR) with OS at the trial- and patient-level.
